8-K: OneMedNet Navigates Auditor Change and Nasdaq Compliance Issues While Securing New Financing

OneMedNet Corporation is addressing a delay in filing its quarterly report, a change in auditors, and has secured a new financing agreement while regaining compliance with a Nasdaq listing rule.

Summary

• OneMedNet Corporation received a notice from Nasdaq for failing to file its quarterly report for the period ending March 31, 2024, on time.
• The company has 60 days, until August 19, 2024, to submit a plan to regain compliance, and if accepted, could be granted up to 180 days, until December 11, 2024, to file the report.
• This delay was caused by the dismissal of their previous auditor, BF Borgers, who were banned by the SEC, and the subsequent appointment of WithumSmith+Brown as their new auditor.
• OneMedNet has regained compliance with Nasdaq's minimum bid price rule, after its stock price remained above $1.00 for 10 consecutive days.
• The company has entered into a standby equity purchase agreement with Yorkville Advisors Global for up to $25 million over the next 24 months, with an initial $1.5 million advance via a convertible promissory note.
• The new financing agreement replaces a previous agreement with Helena Global Investment Opportunities 1 Ltd., which was terminated.
• OneMedNet is working to complete and file its delayed quarterly report as soon as possible.

Sentiment

Score: 4

Explanation: The document highlights significant challenges, including a delay in financial reporting and a change in auditors due to regulatory issues. While the company has secured new financing and regained compliance with a minimum bid price rule, the overall sentiment is negative due to the compliance issues and potential risks.

Positives

• OneMedNet has regained compliance with Nasdaq's minimum bid price rule, indicating improved stock performance.
• The company has secured a significant financing agreement with Yorkville Advisors Global, providing up to $25 million in capital.
• The appointment of a new auditor, WithumSmith+Brown, addresses the issues caused by the previous auditor's ban.
• The company is actively working to file its delayed quarterly report and regain compliance with Nasdaq listing rules.

Negatives

• OneMedNet received a Nasdaq notice for failing to file its Q1 2024 report on time, indicating a potential compliance issue.
• The delay in filing the quarterly report was caused by the dismissal of their previous auditor, which was due to SEC action.
• The company has a limited time frame to submit a plan to regain compliance with Nasdaq listing rules.

Risks

• There is no guarantee that Nasdaq will accept OneMedNet's plan to regain compliance.
• The company may not be able to file its quarterly report within the extended deadline.
• The new financing agreement is subject to certain conditions and limitations.
• The company's stock price could be negatively impacted if it fails to regain compliance with Nasdaq listing rules.

Future Outlook

OneMedNet plans to use the proceeds from the promissory note and the potential offering of common shares for working capital and other general corporate purposes. The company is focused on completing and filing its delayed quarterly report and regaining compliance with Nasdaq listing rules.

Management Comments

• Aaron Green, OneMedNet's President and CEO, stated that the company has been successfully navigating through several interconnected corporate challenges.
• He also mentioned that he is happy to provide an interim report on the company's progress and looks forward to keeping investors updated.

Industry Context

The issues faced by OneMedNet, including auditor changes and compliance issues, are not uncommon in the current regulatory environment. The company's focus on real-world data and its iRWD platform positions it in a growing market, but it must address its compliance issues to maintain investor confidence.

Comparison to Industry Standards

• The delay in filing the quarterly report is a significant issue, as timely financial reporting is a key requirement for Nasdaq-listed companies.
• Other companies in the healthcare data space, such as IQVIA and Flatiron Health, typically maintain strict compliance with reporting deadlines.
• The change in auditors due to regulatory issues is also a concern, as it can raise questions about the reliability of past financial statements.
• The new financing agreement with Yorkville is a positive step, but the terms, including the discount on stock purchases, should be carefully evaluated against industry norms.
• The company's ability to regain compliance with Nasdaq listing rules will be a key indicator of its operational and financial health.

Stakeholder Impact

• Shareholders may be concerned about the delay in financial reporting and the potential for delisting.
• Employees may be affected by the uncertainty surrounding the company's compliance issues.
• Customers and suppliers may be impacted by any potential disruptions to the company's operations.
• Creditors may be concerned about the company's financial stability.

Next Steps

• OneMedNet must submit a plan to Nasdaq to regain compliance with listing rules by August 19, 2024.
• The company needs to complete and file its delayed quarterly report as soon as possible.
• OneMedNet will need to manage the new financing agreement with Yorkville Advisors Global.
• The company will need to continue to work with its new auditor, WithumSmith+Brown.

Key Dates

Keywords

Nasdaq, compliance, auditor, financing, quarterly report, delisting, equity purchase agreement, real world data, financial statements